On August 19, Accuray Incorporated (NASDAQ:ARAY) held its fiscal fourth-quarter and full-year 2026 earnings call, laying out a business caught between a genuine financial rescue and a China market that is still bleeding revenue. Total net revenue fell 21% in the quarter to $100.9 million, and the company won’t even offer a forecast for the year ahead.
A Balance Sheet Finally Gets Fixed
The headline news is the TCW Asset Management transaction. TCW converted $40 million of existing term debt into preferred equity, added a $15 million cash investment through convertible preferred shares, and opened up a $5 million delayed draw facility. The deal also waives certain covenants through December 31, 2027. Cash and restricted cash rose to $48.8 million from $44.4 million the prior quarter, and net inventory dropped $9.6 million as finished goods built earlier in the year finally shipped.
That liquidity relief lands alongside real cost discipline. CEO Stephen LaNeve said the company’s transformation plan delivered more than $20 million in cost and margin improvement during fiscal 2026, beating its original $12 million target, and management expects another $15 million in incremental annualized savings in fiscal 2027. Service revenue, the steadier half of the business, grew 6% in the quarter to $60.1 million on pricing actions and a larger installed base, and the contract capture rate across active systems sits near 90%. Accuray also struck nonbinding letters of intent with Samsung Medison and expanded its work with Tata Consultancy Services, plus a 10-year research collaboration with the University of Wisconsin School of Medicine and Public Health. LaNeve pointed to ESTRO 26, where the European debut of the Stellar platform and continued interest in CyberKnife drove a year-over-year increase in qualified commercial leads.
China Keeps Cutting Into Growth
The bear case starts with product revenue, which fell 42% in the quarter to $40.8 million. Management attributed a $58 million full-year decline specifically to China, citing what LaNeve called “geopolitical developments, trade policy uncertainty, tariff impacts, conditions in China and the Middle East.” Full fiscal-year revenue came in at $401.9 million, down 12%, and order backlog fell 27% year over year to $312.5 million. The book-to-bill ratio was just 0.9 in the quarter, well below the 1.2x level management has called healthy for a growing backlog.
The margin picture is murkier than the headline numbers suggest. Product gross margin was reported at 31.7% for the quarter, but $5.8 million of that came from a one-time favorability tied to the invalidation of IEEPA tariff expenses. Strip that out and adjusted product gross margin was just 17.5%. The company swung to a full-year operating loss of $26.4 million from operating income of $7.8 million a year earlier, and adjusted EBITDA for the year dropped to $10.6 million from $28.3 million. Management chose not to issue formal revenue or EBITDA guidance for fiscal 2027, citing ongoing order-timing risk from trade policy.
What the Market Is Pricing In
Hedge fund ownership climbed from 11 funds to 13 in the most recent quarter, a modest but positive shift in institutional interest. Short interest sits at 4.48% of float, a level that suggests some organized skepticism without signaling a crowded bearish trade. From these figures, it’s hard to say how much of the turnaround story is already reflected in the stock.
Conclusion
Accuray heads into fiscal 2027 with a materially stronger balance sheet than it had a year ago, but the two halves of its business are pulling in different directions. Service revenue and cost savings are compounding in the company’s favor, while product sales in China remain hostage to tariff policy the company has no control over. For the bull case to hold, the new partnerships and transformation savings need to translate into actual order growth once the book-to-bill ratio climbs back toward management’s 1.2x target.
READ NEXT: 10 Best Future Stocks to Buy Under $10 and 12 Best Performing Semiconductor Stocks to Invest In.
Disclosure: None. Follow Insider Monkey on Google News.
